Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA) has begun marketing a 150 mg dosage generic version of the depression treatment Wellbutrin.
Teva already markets a 300 mg version of the drug.
The firm announced that it has begun commercially shipping bupropion hydrochloride extended-release tablets in a 150 mg dose, pursuant to its March 2007 agreement with Anchen Pharmaceuticals, Inc. Anchen is the original manufacturer of Wellbutrin, which is marketed by GlaxoSmithKline
The active ingredient is also used in treatments to help stop smoking.
US sales of the 150 mg dosage Wellbutrin totaled about $930 million for the 12 months ended March 2008, according to IMS data.
Shares in Teva rose 1.35% to $45.73 in Nasdaq trading on Friday, reaching a market cap of $35.3 billion.
Published by Globes [online], Israel business news - www.globes-online.com - on June 1, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008